Balaban DV, Marin FS, Manucu G, Zoican A, Ciochina M, Mina V, Patoni C, Vladut C, Bucurica S, Costache RS, Ionita-Radu F, Jinga M. Clinical characteristics and outcomes in carbohydrate antigen 19-9 negative pancreatic cancer. World J Clin Oncol 2022; 13(7): 630-640 [PMID: 36157158 DOI: 10.5306/wjco.v13.i7.630]
Corresponding Author of This Article
Daniel Vasile Balaban, MD, PhD, Senior Lecturer, Department of Gastroenterology, Carol Davila University of Medicine and Pharmacy, Dr. Carol Davila Central Military Emergency University Hospital, Dionisie Lupu 37, Bucharest 020021, Romania. vbalaban@yahoo.com
Research Domain of This Article
Oncology
Article-Type of This Article
Retrospective Cohort Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jul 24, 2022; 13(7): 630-640 Published online Jul 24, 2022. doi: 10.5306/wjco.v13.i7.630
Clinical characteristics and outcomes in carbohydrate antigen 19-9 negative pancreatic cancer
Daniel Vasile Balaban, Flavius Stefan Marin, George Manucu, Andreea Zoican, Marina Ciochina, Victor Mina, Cristina Patoni, Catalina Vladut, Sandica Bucurica, Raluca Simona Costache, Florentina Ionita-Radu, Mariana Jinga
Daniel Vasile Balaban, Flavius Stefan Marin, George Manucu, Andreea Zoican, Marina Ciochina, Victor Mina, Cristina Patoni, Sandica Bucurica, Raluca Simona Costache, Florentina Ionita-Radu, Mariana Jinga, Department of Gastroenterology, Carol Davila University of Medicine and Pharmacy, Dr. Carol Davila Central Military Emergency University Hospital, Bucharest 020021, Romania
Flavius Stefan Marin, Department of Gastroenterology and Digestive Oncology, Hôpital Cochin, Paris 75014, France
Catalina Vladut, Department of Gastroenterology, Carol Davila University of Medicine and Pharmacy, Prof Dr. Agrippa Ionescu Clinical Emergency Hospital, Bucharest 020021, Romania
Author contributions: Balaban DV proposed the research idea; Balaban DV, Marin FS, Manucu G and Zoican A drafted the study design; Jinga M critically reviewed the manuscript; all authors were involved in patient recruitment, data analysis, literature review and drawing of figures and tables and contributed to the initial version of the manuscript.
Institutional review board statement: Local Ethics Committee approval no. 345/25.07.2019.
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: All authors declare no conflict of interest.
Data sharing statement: Data sharing is available upon request from the corresponding author.
STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Daniel Vasile Balaban, MD, PhD, Senior Lecturer, Department of Gastroenterology, Carol Davila University of Medicine and Pharmacy, Dr. Carol Davila Central Military Emergency University Hospital, Dionisie Lupu 37, Bucharest 020021, Romania. vbalaban@yahoo.com
Received: March 31, 2022 Peer-review started: March 31, 2022 First decision: April 28, 2022 Revised: May 19, 2022 Accepted: July 6, 2022 Article in press: July 6, 2022 Published online: July 24, 2022 Processing time: 112 Days and 16.2 Hours
ARTICLE HIGHLIGHTS
Research background
Carbohydrate antigen 19-9 (CA 19-9) is the most widely used biomarker for pancreatic ductal adenocarcinoma (PDAC), but its use is hindered by both false-positive and false-negative results.
Research motivation
There are inconsistent results regarding the outcome of CA 19-9 negative PDAC cases.
Research objectives
To delineate the phenotype of negative CA 19-9 PDAC according to clinical features, disease staging and outcome.
Research methods
Retrospective single-center analysis of PDAC cases over a period of 30 mo.
Research results
Among 111 recruited patients, 29 had normal CA 19-9. Patients with elevated CA 19-9 had higher tumor burden and more advanced staging. Six-month survival was higher for the negative CA 19-9 group (58.62% vs 47.56%).
Research conclusions
Negative CA 19-9 PDAC has a better prognosis than PDAC with high CA 19-9 values. CEA and CA 125 can be adjunctive useful markers for PDAC, especially in CA 19-9 negative cases.
Research perspectives
Negative CA 19-9 PDAC cases warrant in-depth analysis of tumor biology to assess if there is indeed a different phenotype of neoplasia.
